Last reviewed · How we verify
SHR1459 fasted in P1, high-fat diet in P2
SHR1459 fasted in P1, high-fat diet in P2 is a Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd.. It is currently in Phase 1 development.
At a glance
| Generic name | SHR1459 fasted in P1, high-fat diet in P2 |
|---|---|
| Sponsor | Jiangsu HengRui Medicine Co., Ltd. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SHR1459 fasted in P1, high-fat diet in P2 CI brief — competitive landscape report
- SHR1459 fasted in P1, high-fat diet in P2 updates RSS · CI watch RSS
- Jiangsu HengRui Medicine Co., Ltd. portfolio CI
Frequently asked questions about SHR1459 fasted in P1, high-fat diet in P2
What is SHR1459 fasted in P1, high-fat diet in P2?
SHR1459 fasted in P1, high-fat diet in P2 is a Small molecule drug developed by Jiangsu HengRui Medicine Co., Ltd..
Who makes SHR1459 fasted in P1, high-fat diet in P2?
SHR1459 fasted in P1, high-fat diet in P2 is developed by Jiangsu HengRui Medicine Co., Ltd. (see full Jiangsu HengRui Medicine Co., Ltd. pipeline at /company/jiangsu-hengrui-medicine-co-ltd).
What development phase is SHR1459 fasted in P1, high-fat diet in P2 in?
SHR1459 fasted in P1, high-fat diet in P2 is in Phase 1.